Date: 2015-01-06
Type of information: Series C financing round
Company: AveXis (USA - CA)
Investors: Deerfield Management (USA) Roche Venture Fund (Switzerland)
Amount: $10 million
Funding type: series C financing round
Planned used: Proceeds from the financing will be used to further the development of Avexis\' gene therapy product, chariSMA™, including additional support for the current Phase I clinical trial in spinal muscular atrophy Type 1 infants. The Research Institute at Nationwide Children’s Hospital received IND approval and Fast Track designation in September 2013. The trial is currently open for enrollment and recruiting candidates (NCT02122952). chariSMA™ is an adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene. Last September, the FDA has granted orphan drug designation for this gene therapy for the treatment of spinal muscular atrophy.
Others: * On January 6, 2015, AveXis, a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA),announced it has completed a $10 million financing round led by Deerfield Management and Roche Venture Fund. In conjunction with this financing round, Jonathan Leff of Deerfield and Carole Nuechterlein of Roche Venture Fund will join the Company’s Board of Directors.
Therapeutic area: Rare diseases - Neuromuscular diseases - Neurodegenerative diseases
